Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
520-27-4
Molecular formula
C28H32O15
Molecular weight
608.5 g/mol
Drug class
Flavonoid venotonic and vasoprotective agent (often supplied in micronised purified flavonoid fraction)
Mechanism of action
Reduces venous distensibility and venous stasis, improves venous tone, decreases capillary permeability and fragility, and supports lymphatic drainage. These effects are attributed to modulation of noradrenergic signalling and inflammatory mediators; the full molecular mechanism is not completely defined.
Indications / reported uses
Symptomatic treatment of chronic venous disease, including heaviness, pain and swelling of the legs, where authorised
Short-term treatment of symptoms of acute haemorrhoidal disease in product-authorised settings
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Diosmin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Diosmin Permitted Daily Exposure (PDE) report (the Diosmin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Diosmin Occupational Exposure Limit (OEL) report (the Diosmin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.